ArticleRadiation oncology (London, England)2026
Consolidative radiation in the management of relapsed/refractory Hodgkin lymphoma: a single institution study.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background5-30% of Hodgkin Lymphoma (HL) patients are refractory to primary therapy or have disease relapse requiring additional salvage treatment. High-dose chemotherapy with autologous stem cell transplant (ASCT) is the current standard of care for refractory and recurrent HL. The utility of consolidative RT in the peri-transplant setting has been heavily disputed in recent years. The goal of this study is to evaluate the impact of consolidative radiotherapy in the setting of ASCT in patients with relapsed/refractory HL.
methodsWe retrospectively reviewed 179 consecutive patients with HL who underwent salvage chemotherapy followed by high dose chemotherapy and an ASCT for relapsed (63.4%) or refractory (36.6%) disease with or without subsequent consolidative RT from 2000 to 2019 at our institution.
resultsMedian follow up was 59.4 months. Post-transplant consolidative RT was delivered to 72 patients (40%) at a median dose of 36 Gray (Gy). Nearly two-thirds (46/72, 63.8%) of patients received involved site radiation therapy. Consolidative RT was associated with younger age (median 32 vs. 42 years, p < 0.001), stage I-II disease at the time of salvage chemotherapy (76.4% vs 52.3%, p = 0.001), and no prior RT (76.4% vs 45.8%, p < 0.001). Univariate analysis revealed consolidative RT was associated with an improved 2-year PFS rate (84.1% vs 64.1%, p = 0.005) and OS rate (95.7% vs 80.8%, p = 0.017). In the Cox regression analysis, PFS was associated with consolidative RT (HR: 0.492, 95% CI: 0.288-0.84, p = 0.009) along with ECOG performance status < 2 (HR: 0.188, 95% CI: 0.045-0.79, p = 0.022), complete response to salvage chemotherapy (HR: 0.463, 95% CI: 0.233-0.92, p = 0.028), and stage I-II disease (HR: 0.546, 95% CI: 0.325-0.918, p = 0.022). Similarly, OS was associated with consolidative RT (HR: 0.398, 95% CI: 0.205-0.771, p = 0.006) and ECOG performance status < 2 (HR: 0.073, 95% CI: 0.016-0.333, p = 0.001). Subset analysis suggested that RT was associated with an improved PFS and OS even in those with complete response or non-bulky disease after ASCT. Minimal toxicity was observed in irradiated patients and no deaths were associated with treatment toxicity.
conclusionsPeri-transplant consolidative RT for the salvage management of HL is an effective, complimentary, and well tolerated addition to ASCT for the treatment of relapsed and refractory HL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.